Myostatin Inhibitor vs RAD-140 (Testolone)
A side-by-side research comparison of Myostatin Inhibitor and RAD-140 (Testolone) across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Myostatin Inhibitor | RAD-140 (Testolone) |
|---|---|---|
| Full name | Myostatin Inhibitor Peptides (Anti-GDF-8) | Testolone (RAD-140) |
| Category | Muscle Growth | Muscle Growth |
| Status | Research compound | Investigational (not approved; banned in sport) |
| Mechanism | Propeptide mimics bind mature myostatin; peptide aptamers block ActRIIB; small antagonists compete for receptor. All prevent myostatin-mediated suppression of muscle growth. | Acts as a strong, tissue-selective androgen receptor agonist in muscle and bone, driving anabolic signaling with a higher anabolic-to-androgenic ratio than testosterone in preclinical models. |
| Molecular weight | 2,000-15,000 Da (varies) | 393.83 Da |
| Half-life | 4-48 hours (design-dependent) | ~16-20 hours |
| Bioavailability | Variable (SubQ) | Oral |
| Typical dose | 50-500 mcg | Commonly cited 5-15 mg/day (research) |
| Frequency | 3-7x per week | Once daily |
| Route | Subcutaneous | Oral |
Myostatin Inhibitor reported benefits
- Muscle growth promotion
- Strength increase
- Myostatin blockade
- Muscle wasting treatment potential
- Metabolic improvement
RAD-140 (Testolone) reported benefits
- Strong lean muscle gains (research)
- Increased strength
- Studied originally for muscle wasting and breast cancer
- Bone-supportive signaling
Related comparisons
Research and educational reference only. Not medical advice.